Ketamine + Cognitive Training for Suicidality in the Medical Setting

This Phase IV interventional trial (n=200) aims to assess the effectiveness of Ketamine + Cognitive Training for Suicidality in the Medical Setting.

Led by Rebecca Price from the University of Pittsburgh, the study commenced in March 2021 and is estimated to complete by March 2026. The project seeks to understand the immediate and long-term impact of a single dose of intravenous ketamine on suicidal patients referred for psychiatric consultation in medical inpatient settings. Additionally, the study will investigate whether the rapid effects of ketamine can be prolonged by introducing helpful information through computer-based cognitive training.

The primary outcome measures include the Scale for Suicide Ideation, the Montgomery Asberg Depression Rating Scale, and measures of suicidal behaviors assessed at various time points ranging from 24 hours to 12 months post-randomization.

Secondary outcome measures include self-reported depression, performance-based measures of suicidal cognition, and participant satisfaction with the intervention.

The study involves participants aged between 18 and 65 who are medical inpatients referred for psychiatric consultation due to suicidality. Exclusion criteria include conditions such as acute psychosis, significant thought disruption, mania, dementia, and past intolerance to ketamine.

Trial Details

This project seeks to identify the acute and longer-term impact of a single dose of intravenous ketamine among suicidal patients referred for psychiatric consultation/liaison in the medical inpatient setting. The investigators will then test whether ketamine's rapid effects can be extended by introducing helpful information delivered by a computer-based training protocol. This work could ultimately lead to the ability to treat suicidality more efficiently and with broader dissemination by rapidly priming the brain for helpful forms of learning.

NCT Number NCT04578938

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.